Mirikizumab Achieves Primary Endpoints in Phase 3a Trial for Crohn Disease
More than half of patients in the mirikizumab arm achieved clinical remission at week 52.
United Kingdom Eli Lilly Drug Administration Society For Women Health Research Lotus Mallbris Health Research Lotus Mallbris
Source: hcplive.com